Alpha 2.0
Login Register
» Articles » PMID: 27202291

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients

Overview
Journal Value Health
Publisher Elsevier
Specialties Biomedical Engineering
Pharmacology
Public Health
Date 2016 May 21
PMID 27202291
Citations 5
Authors
V P Retel
L M G Steuten
J C Mewes
W H van Harten
Affiliations
Soon will be listed here.
Citing Articles

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.

Seong G, DAngelo S Front Oncol. 2023; 13:1150765.

PMID: 37007160 PMC: 10052453. DOI: 10.3389/fonc.2023.1150765.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Lindenberg M, Retel V, van den Berg J, Geukes Foppen M, Haanen J, van Harten W J Immunother. 2018; 41(9):413-425.

PMID: 30300260 PMC: 6200372. DOI: 10.1097/CJI.0000000000000245.

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

Rohaan M, van den Berg J, Kvistborg P, Haanen J J Immunother Cancer. 2018; 6(1):102.

PMID: 30285902 PMC: 6171186. DOI: 10.1186/s40425-018-0391-1.

Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.

Rubio-Rodriguez D, De Diego Blanco S, Perez M, Rubio-Terres C Pharmacoeconomics. 2017; 35(9):879-893.

PMID: 28551858 DOI: 10.1007/s40273-017-0517-1.

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.

van Harten W, Retel V Ecancermedicalscience. 2016; 10:683.

PMID: 27899956 PMC: 5102688. DOI: 10.3332/ecancer.2016.683.